Division of Respiratory Medicine, Centre for Respiratory Research and Nottingham Respiratory Biomedical Research Unit, University of Nottingham, Clinical Sciences Building, City Hospital, Nottingham NG5 1PB, United Kingdom.
Mol Cell Biol. 2010 Jun;30(12):2874-86. doi: 10.1128/MCB.01527-09. Epub 2010 Apr 19.
Targeted repression of a subset of key genes involved in tissue remodeling is a cardinal feature of idiopathic pulmonary fibrosis (IPF). The mechanism is unclear but is potentially important in disease pathogenesis and therapeutic targeting. We have previously reported that defective histone acetylation is responsible for the repression of the antifibrotic cyclooxygenase-2 gene. Here we extended our study to the repression of another antifibrotic gene, the potent angiostatic chemokine gamma interferon (IFN-gamma)-inducible protein of 10 kDa (IP-10), in lung fibroblasts from patients with IPF. We revealed that this involved not only histone deacetylation, as with cyclooxygenase-2 repression, but also histone H3 hypermethylation, as a result of decreased recruitment of histone acetyltransferases and increased presence of histone deacetylase (HDAC)-containing repressor complexes, histone methyltransferases G9a and SUV39H1, and heterochromatin protein 1 at the IP-10 promoter, leading to reduced transcription factor binding. More importantly, treatment of diseased cells with HDAC or G9a inhibitors similarly reversed the repressive histone deacetylation and hypermethylation and restored IP-10 expression. These findings strongly suggest that epigenetic dysregulation involving interactions between histone deacetylation and hypermethylation is responsible for targeted repression of IP-10 and potentially other antifibrotic genes in fibrotic lung disease and that this is amenable to therapeutic targeting.
靶向抑制组织重塑过程中涉及的一组关键基因是特发性肺纤维化 (IPF) 的主要特征。其机制尚不清楚,但可能对疾病发病机制和治疗靶点具有重要意义。我们之前曾报道过,组蛋白乙酰化缺陷是导致抗纤维化环氧化酶-2 基因抑制的原因。在这里,我们将研究范围扩展到对 IPF 患者肺成纤维细胞中另一种抗纤维化基因——强效血管生成抑制趋化因子γ干扰素 (IFN-γ) 诱导的 10kDa 蛋白 (IP-10) 的抑制作用。我们揭示,这不仅涉及组蛋白去乙酰化,如环氧化酶-2 抑制,还涉及组蛋白 H3 高甲基化,这是由于组蛋白乙酰转移酶募集减少和包含组蛋白去乙酰化酶 (HDAC) 的抑制复合物、组蛋白甲基转移酶 G9a 和 SUV39H1 以及异染色质蛋白 1 在 IP-10 启动子上的增加,导致转录因子结合减少。更重要的是,用 HDAC 或 G9a 抑制剂治疗患病细胞可类似地逆转抑制性组蛋白去乙酰化和高甲基化,并恢复 IP-10 的表达。这些发现强烈表明,涉及组蛋白去乙酰化和高甲基化相互作用的表观遗传失调是导致纤维化肺部疾病中 IP-10 和潜在其他抗纤维化基因靶向抑制的原因,并且这可以通过治疗靶点进行治疗。